This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Asahi Kasei to buy Veloxis Pharmaceuticals through $1.3 billion tender offer

( November 25, 2019, 09:18 GMT | Official Statement) -- MLex Summary: Japan’s Asahi Kasei, a chemical-centered manufacturer, plans to buy US pharmaceutical company Veloxis Pharmaceuticals through a tender offer for Denmark-based Veloxis Pharmaceuticals A/S, which owns 100 percent of the US firm. Asahi Kasei is planning to buy all of the ordinary shares and warrants of Veloxis for 8.9 billion Danish krone ($1.3 billion) in total, through Asahi’s Danish subsidiary. Asahi Kasei is planning to start the tender offer in December, subject to approval from Denmark's financial regulator, according to a statement. The deal is also subject to antitrust clearances.The statement is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections